{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:07:09Z","timestamp":1791137229860,"version":"4.1.0"},"reference-count":56,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,14]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>In pediatric acute myeloid leukemia (pAML) relapse\/refractory (R\/R) disease occurs frequently, but underlying mechanisms are unclear and effective second-line therapeutic options remain limited. Although genomic characterization has advanced targeted treatments, their clinical implementation, particularly in the pediatric field, is hindered by toxicities or resistance due to poor correlation between preclinical and clinical studies. The use of more robust preclinical models is crucial for developing effective therapies. We established 26 patient-derived xenografts (PDXs) of pAML representing 14 high-risk genetic subtypes. These PDXs faithfully recapitulated the molecular complexity and heterogeneity of primary AML, and preserved the immunophenotypic, genomic, and transcriptomic profiles. Clonal and transcriptomic dynamics were tracked from patient samples to their matched PDXs, and vulnerabilities that could be exploited as therapeutic targets were identified, facilitating the evaluation of multifaceted therapeutic strategies. We selected druggable variants and aberrantly activated pathways in KMT2A-rearranged (KMT2A-r) AML and performed an in vitro drug screening of actionable targets exploiting a predictive 3-dimensional coculture model. Promising compounds were tested in vivo in AML PDXs. Among new drugs targeting variants and pathways, we demonstrate that the combination of IACS-010759, a mitochondrial complex I inhibitor, and venetoclax, a B-cell lymphoma 2 inhibitor, reduces AML progression in KMT2A-r PDXs modeling both disease onset and relapse. The combination of venetoclax with IACS-010759 with a stromal targeting drug slowed AML progression in a resistant model. Overall, our study highlights the power of AML PDXs as a translational platform for novel targeted therapy identification. Our preclinical results testing venetoclax with IACS-010759 in KMT2A-r AML strongly support mitochondrial targeting in this genetic AML subtype.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018002","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T21:15:16Z","timestamp":1769202916000},"page":"2153-2167","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Advancing precision therapy in pediatric acute myeloid leukemia through PDX models and mitochondrial targeting"],"prefix":"10.1182","volume":"10","author":[{"given":"Ambra","family":"Da Ros","sequence":"first","affiliation":[{"name":"1Division of Pediatric Hematology, Oncology and Stem Cell Transplant, Department of Women\u2019s and Children\u2019s Health, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4143-8867","authenticated-orcid":false,"given":"Alberto","family":"Peloso","sequence":"additional","affiliation":[{"name":"1Division of Pediatric Hematology, Oncology and Stem Cell Transplant, Department of Women\u2019s and Children\u2019s Health, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Longo","sequence":"additional","affiliation":[{"name":"1Division of Pediatric Hematology, Oncology and Stem Cell Transplant, Department of Women\u2019s and Children\u2019s Health, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Benetton","sequence":"additional","affiliation":[{"name":"1Division of Pediatric Hematology, Oncology and Stem Cell Transplant, Department of Women\u2019s and Children\u2019s Health, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8854-3821","authenticated-orcid":false,"given":"Valentina","family":"Indio","sequence":"additional","affiliation":[{"name":"2Pediatric Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Cairo","sequence":"additional","affiliation":[{"name":"3Champions Oncology, Rockville, MD"},{"name":"4Fondazione Istituto Ricerca Pediatrica Citt\u00e0 della Speranza, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Sandri","sequence":"additional","affiliation":[{"name":"5Istituto di Scienza, Tecnologia e Sostenibilit\u00e0 per lo Sviluppo dei Materiali Ceramici, Consiglio Nazionale delle Ricerche, Faenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Buldini","sequence":"additional","affiliation":[{"name":"1Division of Pediatric Hematology, Oncology and Stem Cell Transplant, Department of Women\u2019s and Children\u2019s Health, University of Padua, Padua, Italy"},{"name":"4Fondazione Istituto Ricerca Pediatrica Citt\u00e0 della Speranza, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7677-7084","authenticated-orcid":false,"given":"Silvia","family":"Bresolin","sequence":"additional","affiliation":[{"name":"4Fondazione Istituto Ricerca Pediatrica Citt\u00e0 della Speranza, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rosato","sequence":"additional","affiliation":[{"name":"6Immunology and Molecular Oncology Unit, Veneto Institute of Oncology, IRCCS, Padua, Italy"},{"name":"7Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pession","sequence":"additional","affiliation":[{"name":"2Pediatric Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Tregnago","sequence":"additional","affiliation":[{"name":"1Division of Pediatric Hematology, Oncology and Stem Cell Transplant, Department of Women\u2019s and Children\u2019s Health, University of Padua, Padua, Italy"},{"name":"4Fondazione Istituto Ricerca Pediatrica Citt\u00e0 della Speranza, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7976-3654","authenticated-orcid":false,"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[{"name":"8Department of Pediatric Hematology and Oncology, IRCCS, Ospedale Pediatrico Bambino Ges\u00f9, Catholic University of the Sacred Heart, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4793-5263","authenticated-orcid":false,"given":"Martina","family":"Pigazzi","sequence":"additional","affiliation":[{"name":"1Division of Pediatric Hematology, Oncology and Stem Cell Transplant, Department of Women\u2019s and Children\u2019s Health, University of Padua, Padua, Italy"},{"name":"4Fondazione Istituto Ricerca Pediatrica Citt\u00e0 della Speranza, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"suppl 1","key":"2026041408011220800_bib1","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/blood-2023-188682","article-title":"Final results of the AIEOP (Associazione Italiana Ematologia\/Oncologia Pediatrica) AML 2013 prospective randomized trial in childhood acute myeloid leukemia (AML)","volume":"142","author":"Locatelli","year":"2023","journal-title":"Blood"},{"issue":"10","key":"2026041408011220800_bib2","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.3390\/cancers13102336","article-title":"Survival following relapse in children with acute myeloid leukemia: a report from AML-BFM and COG","volume":"13","author":"Rasche","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026041408011220800_bib3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2019.02.011","article-title":"Timing of first-in-child trials of FDA-approved oncology drugs","volume":"112","author":"Neel","year":"2019","journal-title":"Eur J Cancer"},{"key":"2026041408011220800_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2021.12.029","article-title":"Targeted inhibitors and antibody immunotherapies: novel therapies for paediatric leukaemia and lymphoma","volume":"164","author":"Brivio","year":"2022","journal-title":"Eur J Cancer"},{"issue":"2","key":"2026041408011220800_bib5","first-page":"146","article-title":"Allogeneic, donor-derived, second-generation, CD19-CAR-T cell for the treatment of pediatric relapsed\/refractory BCP-ALL","volume":"142","author":"del Bufalo","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2026041408011220800_bib6","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13045-022-01376-3","article-title":"Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia","volume":"15","author":"Caruso","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"suppl 1","key":"2026041408011220800_bib7","doi-asserted-by":"crossref","first-page":"10247","DOI":"10.1182\/blood-2022-166790","article-title":"Preclinical development of a CAR-T cell approach targeting the CD84 antigen associated to pediatric acute myeloid leukemia","volume":"140","author":"Pigazzi","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2026041408011220800_bib8","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood.2024024063","article-title":"Honing CAR T cells to tackle acute myeloid leukemia","volume":"145","author":"Haubner","year":"2025","journal-title":"Blood"},{"issue":"4","key":"2026041408011220800_bib9","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/leu.2016.361","article-title":"NUP98-fusion transcripts characterize different biological entities within acute myeloid leukemia: a report from the AIEOP-AML group","volume":"31","author":"Bisio","year":"2017","journal-title":"Leukemia"},{"issue":"6","key":"2026041408011220800_bib10","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1182\/blood.2021012806","article-title":"The menin-MLL1 interaction is a molecular dependency in NUP98 -rearranged AML","volume":"139","author":"Heikamp","year":"2022","journal-title":"Blood"},{"issue":"18","key":"2026041408011220800_bib11","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1182\/bloodadvances.2020002001","article-title":"Thioridazine requires calcium influx to induce MLL-AF6-rearranged AML cell death","volume":"4","author":"Tregnago","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"2026041408011220800_bib12","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","article-title":"The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis","volume":"123","author":"Yokoyama","year":"2005","journal-title":"Cell"},{"issue":"3","key":"2026041408011220800_bib13","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/leu.2010.316","article-title":"MLL partner genes drive distinct gene expression profiles and genomic alterations in pediatric acute myeloid leukemia: an AIEOP study","volume":"25","author":"Pigazzi","year":"2011","journal-title":"Leukemia"},{"issue":"12","key":"2026041408011220800_bib14","doi-asserted-by":"crossref","first-page":"104869","DOI":"10.1016\/j.ejmg.2023.104869","article-title":"Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX\/MEIS1 expression","volume":"66","author":"Juul-Dam","year":"2023","journal-title":"Eur J Med Genet"},{"issue":"10","key":"2026041408011220800_bib15","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41375-024-02351-2","article-title":"Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia","volume":"38","author":"Atar","year":"2024","journal-title":"Leukemia"},{"issue":"22","key":"2026041408011220800_bib16","doi-asserted-by":"crossref","first-page":"5933","DOI":"10.1182\/bloodadvances.2022008503","article-title":"Targeting FOLR1 in high-risk CBF2AT3-GLIS2 pediatric AML with STRO-002 FOLR1\u2013antibody-drug conjugate","volume":"6","author":"Tang","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2026041408011220800_bib17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"2026041408011220800_bib18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41408-024-01143-2","article-title":"Current status and research directions in acute myeloid leukemia","volume":"14","author":"Kantarjian","year":"2024","journal-title":"Blood Cancer J"},{"issue":"7954","key":"2026041408011220800_bib19","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","article-title":"MEN1 mutations mediate clinical resistance to menin inhibition","volume":"615","author":"Perner","year":"2023","journal-title":"Nature"},{"issue":"20","key":"2026041408011220800_bib20","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1182\/blood.2021014304","article-title":"Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies","volume":"140","author":"Thomalla","year":"2022","journal-title":"Blood"},{"issue":"9","key":"2026041408011220800_bib21","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.3324\/haematol.2019.222588","article-title":"Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia","volume":"104","author":"Tausch","year":"2019","journal-title":"Haematologica"},{"issue":"3","key":"2026041408011220800_bib22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41573-022-00615-z","article-title":"Rational combinations of targeted cancer therapies: background, advances and challenges","volume":"22","author":"Jin","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"2026041408011220800_bib23","doi-asserted-by":"crossref","first-page":"579-10","DOI":"10.1038\/s41467-019-14106-0","article-title":"Clonal competition within complex evolutionary hierarchies shapes AML over time","volume":"11","author":"Sand\u00e9n","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"2026041408011220800_bib24","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1038\/s41467-022-29304-6","article-title":"Comparison of clonal architecture between primary and immunodeficient mouse-engrafted acute myeloid leukemia cells","volume":"13","author":"Kawashima","year":"2022","journal-title":"Nat Commun"},{"issue":"24","key":"2026041408011220800_bib25","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1182\/blood-2016-12-758250","article-title":"Clonal selection and asymmetric distribution of human leukemia in murine xenografts revealed by cellular barcoding","volume":"129","author":"Belderbos","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2026041408011220800_bib26","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41392-023-01419-2","article-title":"Patient-derived xenograft models in cancer therapy: technologies and applications","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"2026041408011220800_bib27","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3390\/biomedicines12020394","article-title":"Addressing a pre-clinical pipeline gap: development of the pediatric acute myeloid leukemia patient-derived xenograft program at Texas Children\u2019s Hospital at Baylor College of Medicine","volume":"12","author":"Stevens","year":"2024","journal-title":"Biomedicines"},{"key":"2026041408011220800_bib28","doi-asserted-by":"publisher","DOI":"10.1101\/2022.01.31.478534","article-title":"PDX models of relapsed pediatric AML preserve global gene expression patterns and reveal therapeutic targets","author":"Wunderlich","year":"1  2022","journal-title":"bioRxiv"},{"issue":"11","key":"2026041408011220800_bib29","doi-asserted-by":"crossref","first-page":"108171","DOI":"10.1016\/j.isci.2023.108171","article-title":"Comprehensive characterization of patient-derived xenograft models of pediatric leukemia","volume":"26","author":"Rogojina","year":"2023","journal-title":"iScience"},{"issue":"2","key":"2026041408011220800_bib30","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood-2013-03-491621","article-title":"Results of the AIEOP AML 2002\/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia","volume":"122","author":"Pession","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2026041408011220800_bib31","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.3390\/biomedicines10071530","article-title":"Molecular measurable residual disease assessment before hematopoietic stem cell transplantation in pediatric acute myeloid leukemia patients: a retrospective study by the I-BFM Study Group","volume":"10","author":"Benetton","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"2026041408011220800_bib32","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/bjh.14523","article-title":"Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002\/01 study protocol","volume":"177","author":"Buldini","year":"2017","journal-title":"Br J Haematol"},{"issue":"7","key":"2026041408011220800_bib33","first-page":"557","article-title":"Targeting the plasticity of mesenchymal stromal cells to reroute the course of acute myeloid leukemia","volume":"138","author":"Borella","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2026041408011220800_bib34","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13045-017-0532-x","article-title":"An improved pre-clinical patient-derived liquid xenograft mouse model for acute myeloid leukemia","volume":"10","author":"Her","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"23","key":"2026041408011220800_bib35","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"26","key":"2026041408011220800_bib36","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1016\/j.biomaterials.2008.05.008","article-title":"Design of graded biomimetic osteochondral composite scaffolds","volume":"29","author":"Tampieri","year":"2008","journal-title":"Biomaterials"},{"issue":"10","key":"2026041408011220800_bib37","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"issue":"13","key":"2026041408011220800_bib38","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1182\/bloodadvances.2023012041","article-title":"Venetoclax: a new player in the treatment of children with high-risk myeloid malignancies?","volume":"8","author":"Masetti","year":"2024","journal-title":"Blood Adv"},{"issue":"22","key":"2026041408011220800_bib39","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1182\/blood.V128.22.2780.2780","article-title":"Final report of phase 1 study of the DOT1L inhibitor, pinometostat (EPZ-5676), in children with relapsed or refractory MLL-r acute leukemia","volume":"128","author":"Shukla","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2026041408011220800_bib40","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/13543776.2022.2045947","article-title":"Menin-MLL protein-protein interaction inhibitors: a patent review (2014\u20132021)","volume":"32","author":"Bai","year":"2022","journal-title":"Expert Opin Ther Pat"},{"issue":"3","key":"2026041408011220800_bib41","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.exphem.2014.10.016","article-title":"Targeting BAG-1: a novel strategy to increase drug efficacy in acute myeloid leukemia","volume":"43","author":"Aveic","year":"2015","journal-title":"Exp Hematol"},{"issue":"12","key":"2026041408011220800_bib42","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1016\/j.celrep.2015.12.003","article-title":"MLL-rearranged acute lymphoblastic leukemias activate BCL-2 through H3K79 methylation and are sensitive to the BCL-2-specific antagonist ABT-199","volume":"13","author":"Benito","year":"2015","journal-title":"Cell Rep"},{"issue":"13","key":"2026041408011220800_bib43","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1080\/10428194.2022.2116934","article-title":"Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-rearranged acute myeloid leukemia (AML)","volume":"63","author":"Ball","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2026041408011220800_bib44","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41591-018-0052-4","article-title":"An inhibitor of oxidative phosphorylation exploits cancer vulnerability","volume":"24","author":"Molina","year":"2018","journal-title":"Nat Med"},{"issue":"4","key":"2026041408011220800_bib45","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1006\/jmcc.1998.0655","article-title":"The statistics of synergism","volume":"30","author":"Slinker","year":"1998","journal-title":"J Mol Cell Cardiol"},{"issue":"12","key":"2026041408011220800_bib46","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1182\/blood-2012-10-464677","article-title":"AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model","volume":"121","author":"Wunderlich","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2026041408011220800_bib47","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41591-022-02103-8","article-title":"Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials","volume":"29","author":"Yap","year":"2023","journal-title":"Nat Med"},{"issue":"4","key":"2026041408011220800_bib48","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.3390\/cancers15041344","article-title":"Repurposing atovaquone as a therapeutic against acute myeloid leukemia (AML): combination with conventional chemotherapy is feasible and well tolerated","volume":"15","author":"Stevens","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"12","key":"2026041408011220800_bib49","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/gcc.22806","article-title":"Clonal evolution of acute myeloid leukemia from diagnosis to relapse","volume":"58","author":"Vosberg","year":"2019","journal-title":"Genes Chromosomes Cancer"},{"issue":"8","key":"2026041408011220800_bib50","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1158\/0008-5472.CAN-15-1015","article-title":"Genomic profiling of pediatric acute myeloid leukemia reveals a changing mutational landscape from disease diagnosis to relapse","volume":"76","author":"Farrar","year":"2016","journal-title":"Cancer Res"},{"issue":"5973","key":"2026041408011220800_bib51","first-page":"1650","article-title":"The wnt\/\u03b2-catenin pathway is required for the development of leukemia stem cells in AML","volume":"327","author":"Wang","year":"2010","journal-title":"Science (1979)"},{"issue":"2","key":"2026041408011220800_bib52","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.beha.2019.05.008","article-title":"Venetoclax-based therapies for acute myeloid leukemia","volume":"32","author":"Guerra","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"issue":"2","key":"2026041408011220800_bib53","doi-asserted-by":"crossref","first-page":"380","DOI":"10.20517\/cdr.2021.125","article-title":"Venetoclax resistance: mechanistic insights and future strategies","volume":"5","author":"Ong","year":"2022","journal-title":"Cancer Drug Resist"},{"issue":"11","key":"2026041408011220800_bib54","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1038\/s43018-021-00264-y","article-title":"Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia","volume":"2","author":"Bosc","year":"2021","journal-title":"Nat Cancer"},{"issue":"19","key":"2026041408011220800_bib55","doi-asserted-by":"crossref","first-page":"15019","DOI":"10.3390\/ijms241915019","article-title":"Novel approaches to treatment of acute myeloid leukemia relapse post allogeneic stem cell transplantation","volume":"24","author":"Liberatore","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026041408011220800_bib56","doi-asserted-by":"crossref","first-page":"106942","DOI":"10.1016\/j.leukres.2022.106942","article-title":"Efficacy of FLT3 and IDH1\/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax","volume":"122","author":"Bewersdorf","year":"2022","journal-title":"Leuk Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/7\/2153\/2510672\/blooda_adv-2025-018002-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/7\/2153\/2510672\/blooda_adv-2025-018002-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T12:01:22Z","timestamp":1776168082000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/7\/2153\/566231\/Advancing-precision-therapy-in-pediatric-acute"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":56,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,4,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018002","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,14]]},"published":{"date-parts":[[2026,3,25]]}}}